AMYRIS, Inc. (AMRS) Posts Smaller Q2 Loss

AMYRIS, Inc. (NASDAQ: AMRS) reported Q2 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $9.3 million versus the consensus estimate of $12.36 million.

In light of our progress during the first half of 2014, we are providing guidance for 2014 and beyond.

• Inflows. We continue to expect renewable product sales to be over $32 million, doubling our 2013 renewable product sales, and to achieve positive cash margin from products. In addition, we continue to expect collaboration inflows, a non-GAAP measure, in the range of $60 million to $70 million by the end of the year.
• Expenses. We continue to expect cash operating expenses for R&D and SG&A in the range of $80 million to $85 million and capital expenditures less than $10 million in 2014.
• Earnings. We continue to expect to achieve positive cash flow from operations during the second half of the year and to achieve positive EBITDA in 2015.
• Payback. We expect cash payback for our Brotas biorefinery in the next two years (following 2013 start-up year), based on plant cash contributions of $10 million to $15 million in 2014 and $40 million to $50 million in 2015.

For earnings history and earnings-related data on AMYRIS, Inc. (AMRS) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Super Micro Computer (SMCI) now down nearly 20%